Patrick R Hof, MD Email Patrick Hof
- PROFESSOR | Neuroscience
- PROFESSOR | Geriatrics and Palliative Medicine
- PROFESSOR | Ophthalmology
* Department of Neuroscience
* Computational Neurobiology and Imaging Center
* Laboratory of Neuromorphology
Aging, Alzheimer's Disease, Anatomy, Autism, Brain, Brain Imaging, Cerebral Cortex, Comparative Anatomy, Demyelination, Epilepsy, Evolution, Glutamate (NMDA & AMPA) Receptors, Hippocampus, Magnetic Resonance Imaging, Memory, Mental Retardation, Morphometrics, Neural Networks, Neuro-degeneration/protection, Prefrontal Cortex, Quantitative Neuroanatomy, Synapses, Systems Neuroscience
Multi-Disciplinary Training Areas
Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]
MD, University of Geneva School of Medicine
, The Scripps Research Institute
Specific Clinical/Research Interest:
Experimental neuropathology, neurodegenerative disorders, brain aging; Functional anatomy of the cerebral cortex, comparative neuroanatomy; Computer-assisted morphometry, stereology, microscopy; Magnetic resonance microscopy, functional brain imaging
Current Students: Tuyen Nguyen (PhD)
Postdoctoral Fellows: Camilla Butti, PhD, Timothy Rumbell PhD, Merina Varghese PhD
Research Personnel: Bridget Wicinski, Daniel Dickstein
Summary of Research Studies:
Our research is directed towards the study of selective neuronal vulnerability in dementing illnesses using classical neuropathological as well as modern quantitative immunohistochemical methods. We intend to develop a quantitative, detailed and cohesive definition of neuronal susceptibility to degeneration in the cerebral cortex, by extending data on Alzheimer disease to other dementing disorders as well as animal models of age-related illnesses, and by defining the key neurochemical and morphological characteristics linked to relative vulnerability (or resistance to degeneration) of identified neuronal populations. The regional and laminar distribution in the cerebral cortex of specific neuronal populations is investigated in a variety of neurodegenerative disorders, and quantitatively compared to Alzheimer disease and control brains. In addition, a detailed study of brains from aged patients with no records of neurological and psychiatric disorders is performed in order to define further the limits of normal aging in the brain.
We employ advanced microscopy, high field magnetic resonance imaging, stereologic, and modeling approaches to develop an accurate quantitative assessment of such pathological changes in a region- and layer-specific manner. Neuronal morphology is analyzed in a quantitative manner using intracellular injection of hippocampal and neocortical neurons coupled with computerized reconstruction to assess the degree to which the accumulation of pathologic markers causes dendritic atrophy and spine loss in different subtypes of neocortical pyramidal cells subserving cortical circuits critical for memory and cognition. The characterization of such vulnerable neurons and circuits is fundamental to the design of therapeutic strategies aiming at their protection or rescue. Similar approaches are applied to the neuropathology of schizophrenia and autism.
Finally we are investigating mammalian brain evolution with a focus on cetaceans and great apes. These studies have led us to identify specific neuronal types in parts of the cerebral cortex known to be involved in social awareness, judgment, and attention that can be considered as markers of adaptive mechanisms and functions in response to particular ecological pressure.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Hof did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.